Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Bicarbonate (13C) MR Imaging in Localized Prostate Cancer
NCT05851365Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hyperpolarized bicarbonate 13C in prostate cancer (PCa). Primary endpoint: Proportion of participants with a signal to noise ratio > 2 at 1 day. Started Jul 2023; status: recruiting.
02
Drugs
Hyperpolarized bicarbonate 13C
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05851365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851365.